Drug Database
Back to search

Netherlands· NL-3458509589f1

Byfavo 20 mg, poeder voor oplossing for injectie of infusie

A remimazolam product containing remimazolambesilaat, registered in Netherlands by Paion Pharma GmbH. The same ATC class is registered in 14 of our 19 countries.

ATC N05CD14

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedByfavo 20 mg, poeder voor oplossing f…ATCN05CD14REGISTER NO.NL-3458509589f1PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about remimazolambesilaatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Remimazolam is registered in 14 of 19 countries.

Countries holding a registration under ATC N05CD14 (remimazolam), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search remimazolam products by name

Remimazolam · ATC N05CD14

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
REMIMAZOLAMBESILAAT
Manufacturer
Paion Pharma GmbH
Country
Netherlands (NL)
ATC code
N05CD14
ATC class
Remimazolam
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/20/1505

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

71 interactions on record for remimazolam.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check remimazolam against other medicinesHow interaction checks work

Remimazolam · interactions on record

71 records

  • 4 severe
  • 64 moderate
  • 3 minor

Most severe, free to view

  • MorphineN02AA01severe
  • MorphinN07BC09severe
  • HydrocodoneR05DA03severe
  • CodeineR05DA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Remimazolam in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All remimazolam products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Byfavo
  • Liechtenstein · Byfavo
  • Norway · Byfavo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/349fa5e7-93e8-4bb7-b725-afa7f2217268
GET /v1/drugs/349fa5e7-93e8-4bb7-b725-afa7f2217268?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor oplossing voor injectie of infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/byfavo-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Remimazolam",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp125981",
  "excipients": [
    "DEXTRAAN 40",
    "LACTOSE 1-WATER",
    "NATRIUMHYDROXIDE (E 524)",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "REMIMAZOLAMBESILAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2021/03/26",
  "procedure_number": "EMEA/H/C/005246",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/20/1505",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about remimazolam.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console